key: cord-1017028-j57xnbja
authors: Gharbharan, Arvind; GeurtsvanKessel, Corine H; Jordans, Carlijn C E; Blaauw, Marc; van der Klift, Marjolein; Hassing, Robert-Jan; Smits-Zwinkels, Marijn; Meertens, Maaike; van den Hout, Ella C; de Man, Anne Marie; Hageman, Ilse; Bogers, Susanne; van der Schoot, C Ellen; Swaneveld, Francis; Anas, Adam A; Rokx, Casper; Rijnders, Bart J A
title: Effects of treatment of COVID-19 with convalescent plasma in 25 B-cell depleted patients
date: 2021-07-22
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab647
sha: 46b00aa6536dfc526b45bd14bf32a57839ceb59f
doc_id: 1017028
cord_uid: j57xnbja

25 B-cell depleted patients (24 following anti-CD19/20 therapy) diagnosed with COVID-19, had been symptomatic for a median of 26 days but remained antibody negative. All were treated with convalescent plasma with high neutralizing antibody titers. 21 (84%) recovered, indicating the potential therapeutic effects of this therapy in this particular population.

B-cell depleting therapy is used to treat hematological and autoimmune diseases and as a result of this treatment, an impaired antibody response is observed upon Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Patients that received this type of therapy are at risk for a more severe and protracted course of Coronavirus disease 2019 (COVID-19) [1] . While the overall net therapeutic value of convalescent plasma (ConvP) for hospitalized COVID-19 patients is probably limited, B-cell depleted patients may benefit from exogenous SARS-CoV-2 antibodies [2] . We conducted a prospective cohort study on the effect of treatment with ConvP on the outcome of Bcell depleted patients with COVID-19.

The Dutch Blood Bank (Sanquin), made ConvP available for immunocompromised COVID-19 patients as part of a compassionate use program. The study protocol was approved by the Institutional Review Board (Erasmus MC MEC-2021-0309). Consent was obtained from patients or legal representatives for the use of data available in their health records.

ConvP was donated by patients recovered for at least 14 days from PCR-confirmed SARS-CoV-2 infection and met standard Dutch donor selection criteria. Plasma was collected according to standard procedures and available in 300 mL units. Eligible patients for ConvP therapy had B-cell depletion or dysfunction and were under care for PCR confirmed symptomatic COVID-19. All had undetectable SARS-CoV-2 receptor binding domain (RBD) antibodies. The treating physician decided on the number of ABO-compatible plasma units used in one transfusion episode. A second transfusion episode was allowed in the absence of clinical response. The primary endpoint was survival after ConvP administration. Secondary outcomes were serological and inflammatory responses, time to lifting of isolation and possible treatment related adverse events. Isolation was lifted when symptoms had improved and SARS-CoV-2 genome in nasopharyngeal swabs was undetectable or detected at a Ct value of >34 by PCR, a Ct value that correlates well with replication incompetent virus with the PCR assay that was used [3] .

A c c e p t e d M a n u s c r i p t 5

An anti-SARS-CoV-2 RBD Enzyme Linked Immunosorbent Assay (ELISA) developed by Sanquin Blood Supply or the Euroimmune SARS-CoV2 ELISA was used to select ConvP donors. A cut-off value of >60 arbitrary units (AU)/ml was used for the in-house ELISA while an OD-value ≥ 7 was used for the Euroimmune ELISA. Both correlate well with a SARS-CoV-2 neutralization antibody titer of ≥ 1:160, although outliers do occur [4] . For a few plasma units with a PRNT50 titer of ≥ 1:160, the PRNT50 was performed and the plasma used before the ELISA had been performed [5] . In patients, SARS-CoV-2 RBD total Ig and IgM antibody tests were measured preceding and following transfusion by ELISA (Wantai Biological, Beijing) and optical density (OD) ratios are reported. An OD above a ratio of 10 has been shown to correspond to virus neutralization and both serological assays have been shown to be highly sensitive for the detection of anti-RBD antibodies. When stored serum samples were available a plaque reduction neutralization test (PRNT) was performed as well, following the methods previously described [6] .

One patient was diagnosed with X-linked agammaglobulinaemia and 24 patients had received a Bcell depleting therapy (n=21 rituximab, n=1 blinatumomab, n=1 obinituzumab and n=1 ocrelizumab) for either a hematological (n=15) or auto-immune disorder (n=9) (Supplementary table 1 Possible treatment related adverse events were observed in five patients. One patient had an anaphylactic reaction, while two patients experienced worsening of hypoxemia. Furthermore, a skin rash and an ALAT increase to a peak of 526 U/L were observed in two other patients. All patients eventually recovered from their possible related adverse event.

In the 21 patients that survived, isolation could be lifted at a median of 11 days (IQR 6 -17,5) after transfusion. In two clinically recovered patients SARS-CoV-2 genome was still detected by PCR, with Ct values <34 for 40 and 68 days respectively, while in all 19 other patients SARS-CoV-2 genome was no longer detectable by PCR at day 23.

We describe the largest case series of B-cell depleted COVID-19 patients treated with ConvP. All c c e p t e d M a n u s c r i p t 7 support our findings. In particular, the Recovery investigators describe the effects of therapy with casirivimab and imdevimab for hospitalized COVID-19 patients. Although this study did not focus on immunocompromised patients in particular, it showed a significant and substantial reduction in overall mortality in the subgroup of SARS-CoV-2 antibody negative patients [7] . Additionally, in a case control study, Thompson et al. observed a reduced overall mortality in patients with hematological malignancies treated with ConvP [8] . Our findings are also in line with other smaller case series [9, 10] . Taken together, B-cell depleted patients with COVID-19 without serological evidence of an autologous anti-SARS-CoV-2 antibody response seem to be a distinct subpopulation

where ConvP therapy has a potential benefit and this benefit may be present regardless of symptom duration.

Our study has limitations. Without a control group, a causal relationship between transfusion and recovery cannot be proven. However, the recovery was typically prompt and in sharp contrast with the symptom duration of a median of 26 days at the time of ConvP transfusion. The hypothesized mechanism of action through viral neutralization as well as the fact that seroconversion coincided with clinical recovery and decrease in inflammatory markers suggests a causal effect. Secondly, the dose of plasma nor the dose of antibodies that the patients received were standardized. Therefore, a firm recommendation on the appropriate dose cannot be made. Lastly, the role of SARS-CoV-2 T-cell response in these patients is likely relevant as well but remains to be studied.

Although ConvP is generally considered safe, five patients had an adverse event possibly related to ConvP. Temporary worsening of hypoxemia might be related to binding of virus neutralizing antibodies to virus particles and the resulting antibody dependent enhancement of the inflammatory response in the lungs. Antibody naive individuals might be more at risk for this phenomenon of antibody dependent enhancement, also reported by others [10] . However, in the majority of patients there was no increase in the inflammatory marker CRP after infusion of ConvP, as might have been expected when immune complexes would have activated macrophages to produce IL-6 [11] . Outside the context of a randomized trial we can only speculate whether the progressive hypoxemia observed after transfusion in two patients was related to ConvP administration instead of progression of COVID-19.

A recent report described an immunocompromised patient who was treated with ConvP on 3 occasions over a 32-day period. In this patient viral genome remained detectable and the ConvP treatment was associated with the occurrence and persistence of mutations in the spike gene. The A c c e p t e d M a n u s c r i p t 8 patient eventually passed away [12] . This case led to the hypothesis that the use of ConvP for immunocompromised patients may result in SARS-CoV-2 mutants and their potential spread. In our case series, SARS-CoV-2 genome remained detectable in 2 individuals after ConvP treatment for 40 and 68 days respectively but both patients eventually cleared the virus and recovered from prolonged COVID-19. In the other 19 individuals SARS-CoV-2 viral genome became undetectable soon after transfusion (median 10 days), which indicates a rapid response to ConvP, and suggests that prolonged viral escape during ConvP is rare.

In conclusion, B-cell depleted patients may benefit from antibody-based therapy. Ideally, our observation should be confirmed in randomized clinical trials. These trials are ongoing in hospitalized (Compromise study, EudraCT 2020-006075-15) as well as outpatients (CoV-Early study, NCT04375098) in the Netherlands. M a n u s c r i p t A c c e p t e d M a n u s c r i p t 

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19

Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency -Three consecutive cases and review of the literature

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

SARS-CoV-2 evolution during treatment of chronic infection

A c c e p t e d M a n u s c r i p t 9 Notes Acknowledgments: The authors thank the patients and their families who were willing to participate in this study. A c c e p t e d M a n u s c r i p t 10